The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease.

por Rutgeerts, P
Publicado 1998

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

por Sandborn, W. J., Rutgeerts, P., Gasink, C., Jacobstein, D., Zou, B., Johanns, J., Sands, B. E., Hanauer, S. B., Targan, S., Ghosh, S., de Villiers, W. J. S., Colombel, J.‐F., Feagan, B. G.
Publicado 2018

Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis

por Rutgeerts, P., Feagan, B. G., Marano, C. W., Padgett, L., Strauss, R., Johanns, J., Adedokun, O. J., Guzzo, C., Zhang, H., Colombel, J.‐F., Reinisch, W., Gibson, P. R., Sandborn, W. J.
Publicado 2015

Adalimumab for the treatment of fistulas in patients with Crohn’s disease

por Colombel, J-F, Schwartz, D A, Sandborn, W J, Kamm, M A, D’Haens, G, Rutgeerts, P, Enns, R, Panaccione, R, Schreiber, S, Li, J, Kent, J D, Lomax, K G, Pollack, P F
Publicado 2009